Skip to main content
ABVC BIOPHARMA, INC. logo

ABVC BIOPHARMA, INC. — Investor Relations & Filings

Ticker · ABVC ISIN · US00091F1066 US Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2017-12-29 Regulatory Filings
Country US United States of America
Listing US ABVC

About ABVC BIOPHARMA, INC.

https://abvcpharma.com/

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes drugs and medical devices to address unmet medical needs. The company focuses on advancing a pipeline of botanical, plant-based pharmaceuticals and medical technologies sourced from research institutions. Its therapeutic areas of focus include oncology, ophthalmology, and central nervous system disorders such as major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD). Key products in development include Vitargus®, a biodegradable vitreous substitute for eye surgery, and botanical drug candidates for MDD and ADHD. Additionally, its subsidiary, BioKey, Inc., offers contract development and manufacturing services for nutritional and pharmaceutical products.

Recent filings

Filing Released Lang Actions
NOTIFICATION OF LATE FILING
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It explicitly states that the registrant, American BriVision (Holding) Corporation, was unable to file its Annual Report on Form 10-K for the fiscal year ended September 30, 2017 on time and requests additional time to file it. The document does not contain the actual 10-K report or financial data but is a notification about the delay in filing the 10-K. According to the rules, such a notification is classified as a Regulatory Filing (RNS) because it is a compliance document notifying the SEC of a late filing rather than the report itself.
2017-12-29 English
CURRENT REPORT
Board/Management Information Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated November 29, 2017, reporting the appointment of four new members to the company's board of directors. The content focuses on changes in the board composition, providing biographical details of the new directors and confirming no related transactions or arrangements. There are no financial statements or detailed financial performance data. The primary subject is the announcement of changes in the company's board of directors, which fits the category of Board/Management Information (MANG).
2017-11-29 English
AMENDMENT NO. 1 TO CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K/A, which is an amendment to a Current Report filed with the SEC. It specifically discloses a change in the company's independent registered public accounting firm, which is a typical subject of a Form 8-K. The document includes a consent letter from the former auditor as an exhibit. The content is an announcement of a change in auditor, not a full audit report or annual report. The document length is 3581 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements and filings that do not fit other categories.
2017-11-28 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, specifically reporting a change in the company's independent registered public accounting firm. It details the dismissal of the former auditor and appointment of a new auditor, including disclosures about audit opinions and disagreements. This type of filing is a regulatory announcement about changes in the auditor, not a full audit report or annual report. It fits the category of Regulatory Filings (RNS) as it is a compliance disclosure related to auditor changes and does not contain substantive financial statements or detailed audit results itself.
2017-11-27 English
Regulatory Filings 2017
Regulatory Filings
2017-10-06 English
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a response letter to the SEC staff comments regarding an Amendment No. 4 to a Registration Statement on Form S-1 filed by American Brivision (Holding) Corporation. It discusses revisions made to the Registration Statement, including disclosures about clinical trials, product candidates, and selling stockholders. The document references the Registration Statement and its amendments multiple times and addresses SEC comments on the filing. This type of document is typical of correspondence related to a registration statement filing, which is a regulatory filing rather than a financial report or earnings release. It does not contain financial statements or detailed financial analysis but is a regulatory communication with the SEC. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (7845 characters) and content confirm it is not a report publication announcement or a full report but a regulatory correspondence.
2017-09-22 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.